☰

Karen E. Gascoigne - Publications

Affiliations: 
2005-2008 Faculty of Life Sciences University of Manchester, Manchester, England, United Kingdom 
 2009-2014 Massachusetts Institute of Technology, Cambridge, MA, United States 
 2014- Genetech, Kota Kinabalu, Sabah, Malaysia 
Tree Info Grants Similar researchers PubMed Report error

20/33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Raisner R, Bainer R, Haverty PM, Benedetti KL, Gascoigne KE. Super-enhancer acquisition drives oncogene expression in triple negative breast cancer. Plos One. 15: e0235343. PMID 32584896 DOI: 10.1371/Journal.Pone.0235343  0.305
2019 de Almeida Nagata DE, Chiang EY, Jhunjhunwala S, Caplazi P, Arumugam V, Modrusan Z, Chan E, Merchant M, Jin L, Arnott D, Romero FA, Magnuson S, Gascoigne KE, Grogan JL. Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. Cell Reports. 27: 269-281.e4. PMID 30943407 DOI: 10.1016/J.Celrep.2019.03.008  0.313
2018 Raisner R, Kharbanda S, Jin L, Jeng E, Chan E, Merchant M, Haverty PM, Bainer R, Cheung T, Arnott D, Flynn EM, Romero FA, Magnuson S, Gascoigne KE. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. Cell Reports. 24: 1722-1729. PMID 30110629 DOI: 10.1016/J.Celrep.2018.07.041  0.34
2018 Chang Y, Woessner DW, Lin W, Chen T, Xu B, Fan Y, Tan H, Peng J, Kasper L, Churchman ML, Gerhard DS, Loh ML, Hunger SP, Seth A, Gascoigne K, et al. Abstract IA12: Modeling and targeting CREBBP mutations in relapsed acute lymphoblastic leukemia Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-Ia12  0.307
2018 Raisner R, Bainer R, Chan E, Garcia J, Merchant M, Gascoigne K. Abstract 1483: Targeting oncogenic enhancer activity with a small-molecule CBP/P300 bromodomain inhibitor Cancer Research. 78: 1483-1483. DOI: 10.1158/1538-7445.Am2018-1483  0.348
2017 Romero FA, Murray JM, Lai KW, Tsui V, Albrecht BK, An L, Beresini MH, de Leon Boenig G, Bronner SM, Chan EW, Chen KX, Chen Z, Choo EF, Clagg K, Clark K, ... ... Gascoigne KE, et al. GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP). Journal of Medicinal Chemistry. PMID 28892380 DOI: 10.1021/Acs.Jmedchem.7B00796  0.302
2016 Crawford TD, Romero FA, Lai KW, Tsui V, Taylor AM, de Leon Boenig G, Noland CL, Murray J, Ly J, Choo EF, Hunsaker TL, Chan EW, Merchant M, Kharbanda S, Gascoigne KE, et al. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. Journal of Medicinal Chemistry. PMID 27682507 DOI: 10.1021/Acs.Jmedchem.6B01022  0.325
2016 Conery AR, Centore RC, Neiss A, Keller PJ, Joshi S, Spillane KL, Sandy P, Hatton C, Pardo E, Zawadzke L, Bommi-Reddy A, Gascoigne KE, Bryant BM, Mertz JA, Sims RJ. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife. 5. PMID 26731516 DOI: 10.7554/Elife.10483  0.346
2016 Keller PJ, Conery AR, Centore RC, Bommi-Reddy A, Gascoigne KE, Bryant BM, Mertz JA, Sims RJ. Abstract 4749: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma Cancer Research. 76: 4749-4749. DOI: 10.1158/1538-7445.Am2016-4749  0.355
2015 Rago F, Gascoigne KE, Cheeseman IM. Distinct organization and regulation of the outer kinetochore KMN network downstream of CENP-C and CENP-T. Current Biology : Cb. 25: 671-7. PMID 25660545 DOI: 10.1016/J.Cub.2015.01.059  0.628
2013 Gascoigne KE, Cheeseman IM. Induced dicentric chromosome formation promotes genomic rearrangements and tumorigenesis. Chromosome Research : An International Journal On the Molecular, Supramolecular and Evolutionary Aspects of Chromosome Biology. 21: 407-18. PMID 23793898 DOI: 10.1007/S10577-013-9368-6  0.606
2013 Gascoigne KE, Cheeseman IM. CDK-dependent phosphorylation and nuclear exclusion coordinately control kinetochore assembly state. The Journal of Cell Biology. 201: 23-32. PMID 23530067 DOI: 10.1083/Jcb.201301006  0.637
2012 Gascoigne KE, Cheeseman IM. T time for point centromeres. Nature Cell Biology. 14: 559-61. PMID 22561349 DOI: 10.1038/Ncb2509  0.595
2012 Nishino T, Takeuchi K, Gascoigne KE, Suzuki A, Hori T, Oyama T, Morikawa K, Cheeseman IM, Fukagawa T. CENP-T-W-S-X forms a unique centromeric chromatin structure with a histone-like fold. Cell. 148: 487-501. PMID 22304917 DOI: 10.1016/J.Cell.2011.11.061  0.616
2011 Gascoigne KE, Takeuchi K, Suzuki A, Hori T, Fukagawa T, Cheeseman IM. Induced ectopic kinetochore assembly bypasses the requirement for CENP-A nucleosomes. Cell. 145: 410-22. PMID 21529714 DOI: 10.1016/J.Cell.2011.03.031  0.662
2011 Gascoigne KE, Cheeseman IM. Kinetochore assembly: if you build it, they will come. Current Opinion in Cell Biology. 23: 102-8. PMID 20702077 DOI: 10.1016/J.Ceb.2010.07.007  0.631
2009 Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? Journal of Cell Science. 122: 2579-85. PMID 19625502 DOI: 10.1242/Jcs.039719  0.475
2008 Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell. 14: 111-22. PMID 18656424 DOI: 10.1016/J.Ccr.2008.07.002  0.482
2006 Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, Taylor SS. Validating Aurora B as an anti-cancer drug target. Journal of Cell Science. 119: 3664-75. PMID 16912073 DOI: 10.1242/Jcs.03145  0.508
2005 Kasza A, O'Donnell A, Gascoigne K, Zeef LA, Hayes A, Sharrocks AD. The ETS domain transcription factor Elk-1 regulates the expression of its partner protein, SRF. The Journal of Biological Chemistry. 280: 1149-55. PMID 15531578 DOI: 10.1074/Jbc.M411161200  0.318
Low-probability matches (unlikely to be authored by this person)
2019 Raisner R, Bainer R, Gascoigne K. Abstract 4338: Enhancer mapping in triple negative breast cancer as a tool for biomarker and oncogene discovery Cancer Research. 78: 4329-4329. DOI: 10.1158/1538-7445.Am2018-4329  0.299
2019 Fortin JP, Tan J, Gascoigne KE, Haverty PM, Forrest WF, Costa MR, Martin SE. Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens. Genome Biology. 20: 21. PMID 30683138 DOI: 10.1186/S13059-019-1621-7  0.295
2019 Pillow TH, Adhikari P, Blake RA, Chen J, Del Rosario G, Deshmukh G, Figueroa I, Gascoigne KE, Kamath AV, Kaufman S, Kleinheinz T, Kozak KR, Latifi B, Leipold DD, Li CS, et al. Antibody Conjugation of a Chimeric BET Degrader Enables In Vivo Activity. Chemmedchem. PMID 31674143 DOI: 10.1002/Cmdc.201900497  0.285
2017 Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M, Kharbanda S, Raisner R, Haverty PM, Modrusan Z, Ly J, Choo E, Kaufman S, Beresini MH, Romero FA, ... ... Gascoigne KE, et al. Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer. Cancer Research. PMID 28819026 DOI: 10.1158/0008-5472.Can-17-0314  0.281
2015 Asundi J, Crocker L, Tremayne J, Chang P, Sakanaka C, Tanguay J, Spencer S, Chalasani S, Luis E, Gascoigne K, Desai R, Raja R, Friedman BA, Haverty PM, Polakis P, et al. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3252-62. PMID 25862760 DOI: 10.1158/1078-0432.Ccr-15-0156  0.278
2005 Offman J, Gascoigne K, Bristow F, Macpherson P, Bignami M, Casorelli I, Leone G, Pagano L, Sica S, Halil O, Cummins D, Banner NR, Karran P. Repeated sequences in CASPASE-5 and FANCD2 but not NF1 are targets for mutation in microsatellite-unstable acute leukemia/myelodysplastic syndrome Molecular Cancer Research. 3: 251-260. PMID 15886296 DOI: 10.1158/1541-7786.Mcr-04-0182  0.272
2016 Castillo J, Raisner R, Gascoigne K, Santos GD, Clarke E, Huang A, Lackner M, Mounir Z. Abstract 4516: Evaluating the chromatin state as a predictive biomarker for BET inhibitor sensitivity in hematological malignancies Cancer Research. 76: 4516-4516. DOI: 10.1158/1538-7445.Am2016-4516  0.25
2023 Liu C, Kudo T, Ye X, Gascoigne K. Cell-to-cell variability in Myc dynamics drives transcriptional heterogeneity in cancer cells. Cell Reports. 42: 112401. PMID 37060565 DOI: 10.1016/j.celrep.2023.112401  0.222
2020 Pillow TH, Adhikari P, Blake RA, Chen J, Del Rosario G, Deshmukh G, Figueroa I, Gascoigne KE, Kamath AV, Kaufman S, Kleinheinz T, Kozak KR, Latifi B, Leipold DD, Sing Li C, et al. Front Cover: Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity (ChemMedChem 1/2020) Chemmedchem. 15: 1-1. DOI: 10.1002/Cmdc.201900683  0.221
2021 Dragovich PS, Pillow TH, Blake RA, Sadowsky JD, Adaligil E, Adhikari P, Bhakta S, Blaquiere N, Chen J, Dela Cruz-Chuh J, Gascoigne KE, Hartman SJ, He M, Kaufman S, Kleinheinz T, et al. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties. Journal of Medicinal Chemistry. PMID 33596065 DOI: 10.1021/acs.jmedchem.0c01845  0.181
2016 Conery AR, Centore RC, Neiss A, Keller PJ, Joshi S, Spillane KL, Sandy P, Hatton C, Pardo E, Zawadzke L, Bommi-Reddy A, Gascoigne KE, Bryant BM, Mertz JA, Sims RJ. Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife. 5. PMID 27411486 DOI: 10.7554/eLife.19432  0.161
2005 Kasza A, O'Donnell A, Zeef L, Gascoigne K, Hayes A, Sharrocks AD. RhoA and MAPK pathways converge to regulate SRF gene expression Ukrain'Skyi Biokhimichnyi Zhurnal. 77: 183.  0.078
2000 Rogers BL, Shapter JG, Skinner WM, Gascoigne K. A method for production of cheap, reliable Pt–Ir tips Review of Scientific Instruments. 71: 1702-1705. DOI: 10.1063/1.1150523  0.01
Hide low-probability matches.